Osimertinib (Tagressa) medical insurance price in 2024

Osimertinib is a targeted therapy drug that is a third-generation epidermal growth factor receptor (EGFR) inhibitor and is widely used to treat non-small cell lung cancer (NSCLC).

Osimertinib is currently on the market in China and has been included in medical insurance. Patients can purchase it at domestic hospital pharmacies at a price of about four to five thousand yuan. Please consult the local hospital pharmacy for specific prices and medical insurance reimbursement policies. The cheaper overseas generic drugs are osimertinib, mainly the Laos version and the Bangladeshi version. The price is about a few hundred yuan, which is much cheaper than domestically, and the ingredients are basically the same as the domestic original drug.

As an oral medication, osimertinib is available in tablet form, usually once daily, and can be taken with or without food. Its mechanism of action is mainly to block the growth and spread of tumor cells by inhibiting the activity of EGFR. Compared with first- and second-generation EGFR inhibitors, osimertinib is more selective and has stronger anti-tumor activity against common EGFR mutations such as the T790M mutation, making it an effective drug for the treatment of drug-resistant NSCLC.

Clinical trials have shown that osimertinib has significant efficacy in the treatment of EGFR T790Mpositive advanced NSCLC patients. It can not only significantly extend the progression-free survival (PFS) of patients, but also improve the survival rate of patients. At the same time, the toxic and side effects of osimertinib are relatively low, usually mild to moderate, including diarrhea, rash, fatigue, etc. Therefore, it is considered a safe and effective treatment option.

In addition to being a treatment for advanced NSCLC, osimertinib is also being studied as a first-line treatment for patients with EGFR mutation-positive NSCLC. Several clinical trials have confirmed the potential value of osimertinib in first-line treatment, showing that osimertinib can provide better efficacy and survival benefits compared with traditional treatment options.